Intellia Therapeutics, Inc.

NASDAQ:NTLA

Biotechnology

Healthcare
$9.77 +0.14%

+$0.02 today

Market cap
$1.37B
Beta
1.81
P/E (TTM)
-4.6
EPS (TTM)
-$3.33
52W Low $7.95High $28.25

Volume 7.23M

Average 6.11M

NTLA Operating Cash Flow

Cash generated by the company's core business operations during the period.

Intellia Therapeutics, Inc.NASDAQ: NTLA

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow declines year over year

Q1 FY2026 operating cash flow of $117.35M (cash outflow) fell 21.2% year over year, behind the -3.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 69.4% from the prior quarter. Over 3 fiscal years it compounded at +1.5% a year.

Context

  • Operating cash flow amounted to 515.6% of revenue in FY2025, down 87.2 pp from a year earlier.
  • Operating cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -21.2% toward the trailing-twelve-month pace of -3.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$117.35M+69.4% QoQ
Last fiscal yearDec 2025
-$348.88M+0.0% YoY
LTMMar 2026
-$363.15M-3.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.2%——
1 year+0.0%——
3-year CAGR+1.5%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(348.88M) USD
Year-over-year change
+0.0%

Operating Cash Flow vs competitors

How NTLA compares with its peers on the latest reported figures

  • NTLA's LTM Mar 2026 operating cash flow of $363.15M is the 2nd largest of the 10 companies compared; the peer median is $140.5M.
  • Its year-over-year change of -3.7% is the 6th highest of 10, against a peer median of +3.5%.
  • Operating cash flow amounts to 549.5% of revenue for NTLA, versus a peer median of 363.1%.
NTLA Competitors Peer median
Operating Cash Flow for NTLA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRSPCRISPR Therapeutics AGLTM Sep 2026$374.63M +23.8%-11.4%1488.3%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$363.15M -3.7%+1.5%549.5%
BEAMBeam Therapeutics Inc.LTM Jun 2026$359.38M +4.2%—230.3%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$179.63M -13.9%+2.2%—
QUREuniQure N.V.LTM Mar 2026$172.11M +3.5%+7.1%951.2%
EDITEditas Medicine, Inc.LTM Mar 2026$140.5M -32.5%-2.3%363.1%
SANASana Biotechnology, Inc.LTM Mar 2026$132.55M -35.7%-20.8%—
PGENPrecigen, Inc.LTM Jun 2026$114.17M +72.3%+10.5%133.2%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$101.25M -26.5%+6.9%903.8%
MGTXMeiraGTx Holdings plcLTM Mar 2026$8.28M +107.9%-14.1%10.4%
Peer median (excluding NTLA) $140.5M+3.5%-0.1%363.1%

Competitors are the stored peer set for NTLA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(267.89M)(474.19M)(481.19M)(519.02M)(519.02M)
Depreciation & Amortization6.89M7.57M8.98M10.29M10.29M
Deferred Income Tax8.93M0000
Stock-Based Compensation47.01M91.4M134.05M154.27M154.27M
Change in Working Capital(22.9M)(53.87M)(52.45M)11.88M(73.75M)
Accounts Receivables99K(1.74M)(32.69M)27.94M(951K)
Inventory7.82M0000
Accounts Payables529K(4.58M)2.52M6.8M5.99M
Other Working Capital(31.36M)(47.55M)(22.29M)(22.86M)(78.79M)
Other Non-Cash Items2.94M95.8M(3.47M)(6.3M)79.34M
Operating Cash Flow(225.03M)(333.29M)(394.09M)(348.88M)(348.88M)
Capital Expenditures(12.76M)(58.39M)(13.99M)(5.78M)(5.78M)
Acquisitions (Net)(3M)(44.68M)000
Purchases of Investments(1.02B)(429.03M)(904.46M)(935.57M)(935.57M)
Sales of Investments485.6M647.58M887.1M1.07B1.05B
Other Investing Activities044.83M0020.97M
Investing Cash Flow(550.78M)160.31M(31.35M)125.57M125.57M
Debt Repayment00000
Common Stock Issued693.57M565.79M119.8M176.9M131.49M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities43.12M17.17M10.53M8.85M54.26M
Financing Cash Flow736.69M582.96M130.32M185.75M185.75M
Effect of Forex Changes00000
Net Change in Cash(39.12M)409.98M(295.11M)(37.57M)(37.57M)
Free Cash Flow(237.79M)(391.68M)(408.07M)(354.66M)(354.66M)

Intellia Therapeutics, Inc.

NASDAQ:NTLA

Intrinsic Alpha fair value

Locked

Current Price

$9.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.